Mint Tower Capital Management B.V. Acquires Shares of 150,000 Kenvue Inc. $KVUE

Mint Tower Capital Management B.V. acquired a new stake in shares of Kenvue Inc. (NYSE:KVUE) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 150,000 shares of the company’s stock, valued at approximately $2,588,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. boosted its position in shares of Kenvue by 0.7% during the 4th quarter. Vanguard Group Inc. now owns 234,951,484 shares of the company’s stock valued at $4,052,913,000 after acquiring an additional 1,604,040 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Kenvue by 0.8% during the 4th quarter. Geode Capital Management LLC now owns 49,862,574 shares of the company’s stock valued at $856,778,000 after acquiring an additional 371,322 shares during the last quarter. Norges Bank bought a new position in shares of Kenvue during the 4th quarter valued at approximately $756,862,000. American Century Companies Inc. boosted its position in shares of Kenvue by 22.4% during the 3rd quarter. American Century Companies Inc. now owns 37,046,660 shares of the company’s stock valued at $601,267,000 after acquiring an additional 6,781,640 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in shares of Kenvue by 13.5% during the 3rd quarter. Dimensional Fund Advisors LP now owns 23,127,234 shares of the company’s stock valued at $375,377,000 after acquiring an additional 2,747,952 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Kenvue Stock Performance

Kenvue stock opened at $18.08 on Friday. The company has a 50 day moving average price of $17.41 and a 200-day moving average price of $17.53. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.70 and a current ratio of 0.98. Kenvue Inc. has a fifty-two week low of $14.02 and a fifty-two week high of $22.87. The company has a market capitalization of $34.70 billion, a PE ratio of 21.26, a P/E/G ratio of 1.37 and a beta of 0.54.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.05. Kenvue had a net margin of 10.61% and a return on equity of 20.81%. The firm had revenue of $3.91 billion during the quarter, compared to the consensus estimate of $3.84 billion. During the same quarter in the previous year, the firm posted $0.24 earnings per share. The company’s revenue was up 4.5% on a year-over-year basis. As a group, equities analysts forecast that Kenvue Inc. will post 1.16 earnings per share for the current year.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, May 27th. Investors of record on Wednesday, May 13th were issued a $0.2075 dividend. This represents a $0.83 annualized dividend and a dividend yield of 4.6%. The ex-dividend date was Wednesday, May 13th. Kenvue’s payout ratio is presently 97.65%.

Insiders Place Their Bets

In other Kenvue news, General Counsel Matthew Orlando sold 38,491 shares of the stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $17.66, for a total transaction of $679,751.06. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 1.59% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

KVUE has been the subject of a number of research reports. UBS Group lowered their target price on Kenvue from $19.00 to $18.00 and set a “neutral” rating for the company in a research report on Tuesday, April 7th. Zacks Research raised shares of Kenvue from a “hold” rating to a “strong-buy” rating in a report on Friday, May 8th. Weiss Ratings downgraded shares of Kenvue from a “hold (c)” rating to a “hold (c-)” rating in a report on Friday, May 29th. Canaccord Genuity Group increased their price target on shares of Kenvue from $17.00 to $18.00 and gave the company a “hold” rating in a report on Wednesday, February 18th. Finally, Argus raised shares of Kenvue to a “hold” rating in a report on Friday, March 6th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and twelve have given a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $19.33.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.